Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
Stephen Rd Johnston, Lucy S Kilburn, Paul Ellis, David Dodwell, David Cameron, Larry Hayward, Young-Hyuck Im, Jeremy P Braybrooke, A Murray Brunt, Kwok-Leung Cheung, Rema Jyothirmayi, Anne Robinson, Andrew M Wardley, Duncan Wheatley, Anthony Howell, Gill Coombes, Nicole Sergenson, Hui-Jung Sin, Elizabeth Folkerd, Mitch DowsettJudith M Bliss, SoFEA investigators
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial'. Together they form a unique fingerprint.